Novo Nordisk A/S (NVO): Jim Cramer’s Take on Weight Loss Drug Giant’s Future
We recently published a list of Jim Cramer Discusses These 12 Stocks & Trump DOJ’s Action Against Health Insurance Companies.
Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs
Novo Nordisk shares moved higher Tuesday after telehealth specialist Hims & Hers said that it would stop selling copycat versions of weight-loss drugs produced by the Danish company. Shares in the ...
devdiscourse52m
Eli Lilly's Strategic Price Cut for Zepbound Aims to Outpace Rivals
Eli Lilly has reduced the price of its weight-loss drug, Zepbound, to combat competition from compounding pharmacies and Novo ...
Hims & Hers shares plunge as looming curbs on drug compounding cloud forecast
Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...
NBC2645m
Hims and Hers likely to stop selling cheaper versions of GLP-1 medications
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded versions due to regulatory changes.